Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Glucagon · 1 trial · 1 indication
\< 50mg/dl
\>150mg/dl
| Arm | Type | Description |
|---|---|---|
| Insulin IV | ACTIVE_COMPARATOR | calculated insulin rate |
| Insulin and Glucagon IV | EXPERIMENTAL | calculated molar ratio insulin:glucagon |
| Name | Type | Description |
|---|---|---|
| Glucagon | DRUG | calculated IV insulin:Glucagon molar ratio |
| Insulin | DRUG | calculated IV Insulin dose infused at a constant rate |
Inclusion Criteria: * Male or female patients aged between 18 and 64 years (both inclusive) * Type 1 diabetes mellitus (as diagnosed clinically) ≥ 12 months prior to the screening visit * Treated with daily insulin for T1DM ≥ 12 months prior to the screening visit Exclusion Criteria: \-
Glucagon is being investigated for use in Type 1 Diabetes Mellitus With Hypoglycemia, a condition where blood sugar levels drop dangerously low. It is a small molecule developed by United Therapeutics Corporation. The drug is in early clinical development, with one completed Phase 1 trial studying its effects on glucose levels.
Glucagon is a small molecule that works by raising blood glucose levels, counteracting the effects of insulin. It is being studied in Type 1 Diabetes Mellitus With Hypoglycemia to help manage severe hypoglycemic episodes. The drug's mechanism involves stimulating the liver to release stored glucose into the bloodstream.
Glucagon is being developed by United Therapeutics Corporation, a biopharmaceutical company listed on NASDAQ under the ticker UTHR. The company is conducting clinical research on this small molecule for the treatment of Type 1 Diabetes Mellitus With Hypoglycemia. The drug is currently in Phase 1 clinical development.
Glucagon is in Phase 1 clinical development, specifically an early Phase 1 trial. The study, NCT04712266, has been completed. It is an investigational drug and has not been approved by regulatory authorities. The trial enrolled 15 participants with Type 1 Diabetes Mellitus With Hypoglycemia in the United States.
Glucagon has one completed clinical trial, NCT04712266, titled 'A Trial to Investigate Hyperglycemic and Hypoglycemic Excursions in Subjects With Type 1 Diabetes.' This early Phase 1 study enrolled 15 participants with Type 1 Diabetes Mellitus With Hypoglycemia in the United States. The trial was active-controlled and randomized, though not double-blind.
Glucagon is a small molecule being developed by United Therapeutics Corporation for Type 1 Diabetes Mellitus With Hypoglycemia. It is distinct from other glucagon products on the market, which are typically peptides used for emergency hypoglycemia treatment. This investigational drug is in early clinical development and has not been approved.